Brain Hemorrhage Market

Brain Hemorrhage Market Size (2023 to 2028)

The brain hemorrhage market growth is expected to reach USD 2.7 billion by 2028 from USD 2.0 billion in 2023, with a CAGR of 6.0% during the forecast period 2023 to 2028.

Brain hemorrhage is a critical condition characterized by bleeding between the brain tissue and the skull or within the brain tissue itself. It requires immediate medical attention as it can reduce oxygen supply to the brain, leading to symptoms like headaches, nausea, vomiting, tingling extremities, and facial paralysis. Factors contributing to brain hemorrhage include head trauma, cerebral aneurysm, extremely high blood pressure, liver disease, brain tumor, and illicit drug use.

Treatment of brain hemorrhage depends on the size and location of the bleed and can involve surgical intervention or medication management. In cases of severe brain hemorrhage, surgery may be required to alleviate pressure on the brain. Surgeons may perform a craniotomy, which involves removing part of the skull and clipping the artery if the cause of the incident is a burst cerebral aneurysm. Other treatment options include medication for symptom control, such as anti-anxiety drugs, anti-epileptic drugs, and drugs to manage severe headaches and seizures.

According to the Centers for Disease Control and Prevention (CDC), stroke ranks as the fifth leading cause of death in the United States. Although brain hemorrhages are more prevalent in older adults, they can also occur in children. The National Stroke Association reports that approximately 1 in 4,000 live births are affected by stroke, with a slightly higher incidence in children under 2 years old. Fortunately, children tend to have better outcomes from brain hemorrhages due to their developing brains. Consequently, the growing prevalence of brain hemorrhage is likely to contribute to the expansion of the hemorrhage diagnosis and treatment market.

Market Drivers:

The major factors contributing to the growth of the market are the rise in research and development activities for the development of novel therapeutics, the high incidence of brain hemorrhage, changing lifestyle, government initiatives towards innovation investments, and the rising old-age and pediatric population.

• Increase in cases of brain hemorrhage

The significant occurrence of cerebral aneurysms is projected to drive the expansion of the global brain hemorrhage market throughout the forecast period. For instance, the worldwide prevalence of cerebral aneurysms stood at approximately 3.2%, with a rupture risk leading to subarachnoid hemorrhage observed in approximately 10 cases per 100,000 individuals.

• Research & Development activities

The advancement of novel approaches through R&D is also anticipated to drive the growth of the global brain hemorrhage market during the forecast period. For instance, in 2019, the number of deaths caused by intracerebral hemorrhagic stroke exceeded those attributed to subarachnoid hemorrhagic stroke. In total, more than 3 million individuals succumbed to hemorrhagic stroke in 2019. Furthermore, the five-year survival rate after a brain hemorrhage is relatively low. While a small percentage of individuals, approximately 44% may survive for 30 days, the majority of patients experience mortality within 24 hours. Thus, there is high demand for alternative therapeutics, which can be achieved by novel R&D approaches only.

• Changing lifestyle of society

The growth of the brain hemorrhage treatment market is primarily boosted by the prevalence of stroke, driven by changing lifestyles, and the burden of chronic conditions. Hemorrhagic strokes account for approximately 14-20% of all stroke cases, as reported by the American Stroke Association. The mortality rate among individuals who experience intracerebral hemorrhage ranges from 33% to 65%. The global market is influenced by the increasing incidence of chronic illnesses. Moreover, the elevated utilization of anti-hypertensive medications contributes to a higher risk of hemorrhagic stroke, thus driving the demand for hemorrhagic stroke treatment.

Market Restraints:

The major factors restraining the market are the complications in the treatment of brain hemorrhage can results. For instance, a March 2021 study published in the British Medical Journal found that administering coagulation factors in intracerebral hemorrhage treatment may lead to the formation of blood clots that can travel through the bloodstream. These adverse effects are expected to restrict the expansion of the global brain hemorrhage market. Furthermore, the market is hindered by a scarcity of skilled workforce and stringent FDA approvals. Similarly, market growth is projected to be limited shortly due to stringent FDA regulations and the high cost of treatment. Additionally, the utilization of generic drugs is also impeding market growth

Impact of COVID-19 on the Brain Hemorrhage Market:

The global COVID-19 pandemic had a significant impact on businesses worldwide, disrupting their operations across various industries. To control the rapid spread of the disease, numerous countries implemented lockdown measures, resulting in the temporary closure of manufacturing facilities and a halt in production. The healthcare industry, in particular, encountered significant challenges as the outbreak caused widespread confusion and misinformation, placing immense pressure on hospitals and healthcare systems worldwide.

Likewise, the global brain hemorrhage market was adversely affected by the COVID-19 pandemic since recent research indicates no direct association between brain hemorrhage and COVID-19. Nevertheless, a Stroke medical journal study from June 2021 revealed that only 0.2% (48) out of 21,483 COVID-19 patients experienced intracerebral hemorrhage. Among these 48 COVID-19 patients, 26 were diagnosed with COVID-19 before developing intracerebral hemorrhage, 10 were diagnosed on the same day as the hemorrhage occurred, and 6 were diagnosed with COVID-19 while being hospitalized for intracerebral hemorrhage. The study concludes that intracerebral hemorrhage is infrequent in COVID-19 patients and does not have a direct connection to the occurrence of COVID-19.

.

Report Coverage:

The market of brain hemorrhage is segmented and sub-segmented into drugs, end-users, and regions.

Brain Hemorrhage Market - By Drug Type

• Anti-hypertensive Drugs
• Anti-convulsants Drugs
• Hyperosmotic Drugs
• Others

1. Anti-epileptic Drugs
2. Anti-pyretic Drugs

Based on drug type, during the projection period, the anti-hypersensitive drugs segment is anticipated to grow at a significant CAGR. This growth is attributed to the increasing number of hypertensive patients and the preference of medical professionals for these drugs to reduce the risk of stroke and other complications, as antihypertensive agents effectively lower blood pressure to prevent exacerbation of intracerebral hemorrhage.

On the other hand, anti-convulsants are utilized for acute seizure prophylaxis in individuals with closed-head injuries, making them the second most commonly used drug in the treatment of brain hemorrhage.

Brain Hemorrhage Market - By End-users

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on end-users, the hospital pharmacies segment dominated the market in 2022. Hospitals serve as central hubs for patient care and complex surgical procedures. The increasing preference of patients for hospitals as screening venues, the rise in the number of hospitals in emerging economies, and the strong network of hospitals in developed countries. Growing awareness among the general population and the implementation of screening programs in healthcare facilities further contribute to market growth.

On the other hand, the online pharmacies segment is projected to hold a second dominant position in the global market. This can be attributed to the increasing penetration of the internet and the wide range of products available on e-commerce platforms, offering convenience and variety to consumers.

Brain Hemorrhage Market - By Region

• North America
• Europe
• Asia-Pacific
• The Middle East & Africa
• Latin America

By region, North America dominates the market owing to factors such as increased prevalence of chronic diseases, rising incidence of hemorrhagic stroke, growing healthcare awareness, and others.

Europe accounts for the second-largest market in the overall industry and is projected to expand significantly in the coming years.

Asia Pacific is anticipated to experience the fastest CAGR during the forecast period. The brain hemorrhage treatment market in Asia Pacific is set to expand rapidly due to factors such as increasing product releases, a growing geriatric population, and advancements in healthcare standards, particularly in India and China, in response to the rising prevalence of strokes.

In terms of the rest of the world, it is expected to exhibit considerable growth at a noteworthy CAGR in the anticipated years.

Key Market Players:

Some of the notable key market players include Abbott, F. Hoffmann-La Roche Ltd. Bristol-Myers Squibb, Oxurion NV, Bayer AG, Boehringer Ingelheim, Baxter, Neurotech Pharmaceuticals, H. Lundbeck A/S, Johnson and Johnson, Ligand Pharmaceuticals Incorporated, Novartis AG, Novo Nordisk A/S, Inc., Pfizer, Inc., and Siemens Healthcare GmbH

Recent Market Developments:

1. In Jan 2023, recent research indicates that COVID-19 can affect not only our bodies but also the bodies of unborn babies. Evidence has been discovered showing the presence of the virus in fetal brain tissue when pregnant individuals transmit the infection to their developing infants.
2. In October 2019, the latest addition to iSchemaView, Inc.'s rapid platform, called RAPID ICH, has been launched. This advanced system utilizes artificial intelligence to quickly evaluate non-contrast CT scans and promptly alert clinicians to the potential presence of intracranial hemorrhage.